Skip to content
Products & Services · Net revenues

Qulipta — Net revenues

AbbVie Qulipta — Net revenues increased by 2.8% to $296M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 53.4%, from $193M to $296M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2021
Last reportedQ1 2026May 8, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market penetration, strong physician adoption, and effective commercial execution, while a decrease may signal increased competition, patent cliffs, or loss of market share.

Detailed definition

This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowanc...

Peer comparison

Comparable to branded pharmaceutical product revenue lines at peer companies, often benchmarked against therapeutic area market growth rates and consensus analyst expectations for drug-specific performance.

Metric ID: abbv_segment_qulipta_net_revenues

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$11M$33M$62M$52M$66M$96M$132M$114M$131M$150M$176M$201M$193M$267M$288M$288M$296M
QoQ Change+200.0%+87.9%-16.1%+26.9%+45.5%+37.5%-13.6%+14.9%+14.5%+17.3%+14.2%-4.0%+38.3%+7.9%+0.0%+2.8%
YoY Change+500.0%+190.9%+112.9%+119.2%+98.5%+56.3%+33.3%+76.3%+47.3%+78.0%+63.6%+43.3%+53.4%
Range$0$296M
Avg YoY Growth+113.3%
Median YoY Growth+76.3%
Current Streak4 quarters growth

Frequently Asked Questions

What is AbbVie's qulipta — net revenues?
AbbVie (ABBV) reported qulipta — net revenues of $296M in Q1 2026.
How has AbbVie's qulipta — net revenues changed year-over-year?
AbbVie's qulipta — net revenues increased by 53.4% year-over-year, from $193M to $296M.
What does qulipta — net revenues mean?
The total net sales generated by the specific pharmaceutical product line during the reporting period.